Aptus Capital Advisors LLC Acquires New Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Aptus Capital Advisors LLC acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 551 shares of the medical instruments supplier’s stock, valued at approximately $207,000.

Other hedge funds have also recently modified their holdings of the company. Summit Place Financial Advisors LLC increased its holdings in West Pharmaceutical Services by 2.5% in the third quarter. Summit Place Financial Advisors LLC now owns 1,703 shares of the medical instruments supplier’s stock valued at $639,000 after buying an additional 42 shares in the last quarter. Campbell & CO Investment Adviser LLC raised its holdings in West Pharmaceutical Services by 63.3% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 3,746 shares of the medical instruments supplier’s stock worth $1,406,000 after purchasing an additional 1,452 shares during the period. Pathstone Family Office LLC boosted its position in West Pharmaceutical Services by 12.2% during the third quarter. Pathstone Family Office LLC now owns 4,521 shares of the medical instruments supplier’s stock worth $1,696,000 after purchasing an additional 491 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in West Pharmaceutical Services by 6.4% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 10,940 shares of the medical instruments supplier’s stock valued at $4,105,000 after purchasing an additional 657 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of West Pharmaceutical Services by 1.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 414,724 shares of the medical instruments supplier’s stock valued at $155,609,000 after buying an additional 4,069 shares in the last quarter. Hedge funds and other institutional investors own 91.23% of the company’s stock.

West Pharmaceutical Services Stock Down 0.7 %

Shares of NYSE:WST opened at $406.63 on Tuesday. The company has a market capitalization of $30.09 billion, a price-to-earnings ratio of 54.88, a PEG ratio of 4.04 and a beta of 1.05. West Pharmaceutical Services, Inc. has a 12-month low of $269.94 and a 12-month high of $415.73. The business has a 50-day moving average price of $359.27 and a 200 day moving average price of $367.95. The company has a current ratio of 3.70, a quick ratio of 2.89 and a debt-to-equity ratio of 0.05.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 7th. Investors of record on Wednesday, January 31st were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.20%. The ex-dividend date of this dividend was Tuesday, January 30th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 10.80%.

Insider Activity at West Pharmaceutical Services

In related news, CAO Chad Winters sold 1,013 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $349.00, for a total transaction of $353,537.00. Following the completion of the transaction, the chief accounting officer now directly owns 1,270 shares in the company, valued at approximately $443,230. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.13% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Jefferies Financial Group raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and boosted their target price for the stock from $323.00 to $536.00 in a research note on Wednesday, February 7th. Stephens cut their price objective on West Pharmaceutical Services from $420.00 to $390.00 and set an “overweight” rating for the company in a research note on Friday, October 27th. Finally, StockNews.com raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Thursday, December 7th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, West Pharmaceutical Services currently has a consensus rating of “Buy” and an average price target of $412.20.

Read Our Latest Research Report on WST

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

See Also

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.